肝酶正常化可预测丙型肝炎口服直接抗病毒治疗的成功。
Liver enzyme normalization predicts success of Hepatitis C oral direct-acting antiviral treatment.
作者信息
Khan Sarwat T, McGuinty Michaeline, Corsi Daniel J, Cooper Curtis L
机构信息
University of Ottawa, Ottawa, Canada; The Ottawa Hospital Research Institute, Ottawa, Canada.
出版信息
Clin Invest Med. 2017 Apr 26;40(2):E73-E80. doi: 10.25011/cim.v40i2.28198.
PURPOSE
Monitoring of hepatitis C virus (HCV) treatment response is performed by serial HCV RNA measurements; however, this may not be useful for predicting treatment success or failure with oral direct-acting antiviral agent (DAA) therapies. Liver enzyme levels, which are elevated in chronic HCV and tend to decline on therapy, may serve as a more logistically and economically feasible alternative for monitoring treatment response.
SOURCE
The Ottawa Hospital Viral Hepatitis Clinic patients (n=219), receiving interferon-free oral DAA treatments, were assessed for liver enzymes and HCV RNA levels at baseline, week 4 and ≥12 weeks post-treatment. Suppression cut points used for this analysis were ALT ≤ 40U L-1 and AST ≤ 30U L-1. The primary outcome was week 12 sustained virologic response (SVR). By our analysis, all indicators had strong PPV (>90%) but limited NPV (.
目的
丙型肝炎病毒（HCV）治疗反应的监测通过连续检测HCV RNA来进行；然而，这对于预测口服直接抗病毒药物（DAA）疗法的治疗成功或失败可能并无帮助。肝酶水平在慢性HCV中升高且在治疗时往往会下降，可作为监测治疗反应的在后勤和经济方面更可行的替代方法。
来源
渥太华医院病毒性肝炎诊所的患者（n = 219），接受不含干扰素的口服DAA治疗，在基线、治疗后第4周和≥12周时评估肝酶和HCV RNA水平。该分析使用的抑制切点为ALT≤40U/L-1和AST≤30U/L-1。主要结局为治疗后第12周持续病毒学应答（SVR）。通过我们的分析，所有指标的阳性预测值（PPV）均较高（>90%），但阴性预测值（NPV）有限（。
Zotero 插件